Population Pharmacokinetic Modeling of von Willebrand Factor Activity in von Willebrand Disease Patients after Desmopressin Administration
Objective Most von Willebrand disease (VWD) patients can be treated with desmopressin during bleeding or surgery. Large interpatient variability is observed in von Willebrand factor (VWF) activity levels after desmopressin administration. The aim of this study was to develop a pharmacokinetic (PK) model to describe, quantify, and explain this variability.
Methods Patients with either VWD or low VWF, receiving an intravenous desmopressin test dose of 0.3 µg kg−1, were included. A PK model was derived on the basis of the individual time profiles of VWF activity. Since no VWF was administered, the VWF dose was arbitrarily set to unity. Interpatient variability in bioavailability (F), volume of distribution (V), and clearance (Cl) was estimated.
Results The PK model was developed using 951 VWF activity level measurements from 207 patients diagnosed with a VWD type. Median age was 28 years (range: 5–76), median predose VWF activity was 0.37 IU/mL (range: 0.06–1.13), and median VWF activity response at peak level was 0.64 IU/mL (range: 0.04–4.04). The observed PK profiles were best described using a one-compartment model with allometric scaling. While F increased with age, Cl was dependent on VWD type and sex. Inclusion resulted in a drop in interpatient variability in F and Cl of 81.7 to 60.5% and 92.8 to 76.5%, respectively.
Conclusion A PK model was developed, describing VWF activity versus time profile after desmopressin administration in patients with VWD or low VWF. Interpatient variability in response was quantified and partially explained. This model is a starting point toward more accurate prediction of desmopressin dosing effects in VWD.
N.d.J. wrote the manuscript. J.H. and Q.K. collected the clinical data. N.d.J. and R.M. performed the analyses and developed the empirical population PK model. M.C. supervised data collection. R.M. and M.C. jointly supervised this study, while F.L. and M.K. gave critical guidance. All authors contributed substantially to the critical revision of the manuscript, and approved the final draft.
* Both are first authors.
** Both are last authors.
† See [Supplementary Appendix A] for a full list of members of the study group.
Eingereicht: 08. April 2020
Angenommen: 05. Juni 2020
03. August 2020 (online)
© 2020. Thieme. All rights reserved.
Georg Thieme Verlag KG
Stuttgart · New York
- 1 Leebeek FWG, Eikenboom JCJ. Von Willebrand's disease. N Engl J Med 2016; 375 (21) 2067-2080
- 2 Roberts JC, Morateck PA, Christopherson PA. , et al; Zimmerman Program Investigators. Rapid discrimination of the phenotypic variants of von Willebrand disease. Blood 2016; 127 (20) 2472-2480
- 3 Matsui T, Hamako J. von Willebrand factor and von Willebrand disease. Rinsho Ketsueki 2016; 57 (10) 2113-2123
- 4 Sadler JE, Budde U, Eikenboom JC. , et al; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4 (10) 2103-2114
- 5 Favaloro EJ, Pasalic L, Curnow J. Monitoring therapy during treatment of von Willebrand disease. Semin Thromb Hemost 2017; 43 (03) 338-354
- 6 Gill JC, Castaman G, Windyga J. , et al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood 2015; 126 (17) 2038-2046
- 7 Laffan MA, Lester W, O'Donnell JS. , et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol 2014; 167 (04) 453-465
- 8 Stoof SCM, Cnossen MH, de Maat MPM, Leebeek FWG, Kruip MJHA. Side effects of desmopressin in patients with bleeding disorders. Haemophilia 2016; 22 (01) 39-45
- 9 Nichols WL, Hultin MB, James AH. , et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14 (02) 171-232
- 10 Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet 1977; 1 (8017): 869-872
- 11 Lethagen S, Harris AS, Sjörin E, Nilsson IM. Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibility. Thromb Haemost 1987; 58 (04) 1033-1036
- 12 de la Fuente B, Kasper CK, Rickles FR, Hoyer LW. Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressin. Ann Intern Med 1985; 103 (01) 6-14
- 13 Mannucci PM, Vicente V, Alberca I. , et al. Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: pharmacokinetics and factor VIII responses. Thromb Haemost 1987; 58 (04) 1037-1039
- 14 Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet 1977; 1 (8017): 869-872
- 15 Hörl W. Other blood and immune disorders in chronic kidney disease. Comprhensive Clinical Nephrology 2010; 84: 959-968
- 16 Mannucci PM. Desmopressin: an historical introduction. Haemophilia 2008; 14 (Suppl. 01) 1-4
- 17 Heijdra JM, Cnossen MH, Leebeek FWG. Current and emerging options for the management of inherited von Willebrand disease. Drugs 2017; 77 (14) 1531-1547
- 18 Federici AB, Mazurier C, Berntorp E. , et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 2004; 103 (06) 2032-2038
- 19 Nederlandse Vereniging van Hemofiliebehandelaars (NVHB). Richtlijn: diagnostiek en behandeling van hemofilie en aanverwante hemostasestoornissen. Alphen aan den Rijn: Van Zuiden Commun BV. 2009
- 20 Bodó I, Eikenboom J, Montgomery R. , et al. Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13 (07) 1345-1350
- 21 de Wee EM, Sanders YV, Mauser-Bunschoten EP. , et al; WiN study group. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. Thromb Haemost 2012; 108 (04) 683-692
- 22 Atiq F, Meijer K, Eikenboom J. , et al; WiN study group. Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease. Br J Haematol 2018; 182 (01) 93-105
- 23 Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005; 79 (03) 241-257
- 24 Keizer RJ, van Benten M, Beijnen JH, Schellens JHM, Huitema ADR. Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed 2011; 101 (01) 72-79
- 25 Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming. Comput Methods Programs Biomed 2004; 75 (02) 85-94
- 26 Preijers T, Hazendonk HCAM, Liesner R. , et al; OPTI-CLOT study group. Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery. J Thromb Haemost 2018; 16 (11) 2196-2207
- 27 Sanders YV, Giezenaar MA, Laros-van Gorkom BAP. , et al; WiN study group. von Willebrand disease and aging: an evolving phenotype. J Thromb Haemost 2014; 12 (07) 1066-1075
- 28 Lip GYH, Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders?. Cardiovasc Res 1997; 34 (02) 255-265
- 29 Stachenfeld NS, Splenser AE, Calzone WL, Taylor MP, Keefe DL. Sex differences in osmotic regulation of AVP and renal sodium handling. J Appl Physiol (1985) 2001; 91 (04) 1893-1901
- 30 Flood VH. Perils, problems, and progress in laboratory diagnosis of von Willebrand disease. Semin Thromb Hemost 2014; 40 (01) 41-48
- 31 Michelet R, Dossche L, Van Herzeele C, Van Bocxlaer J, Vermeulen A, Vande Walle J. ; SAFE-PEDRUG consortium. Claiming desmopressin therapeutic equivalence in children requires pediatric data: a population PKPD analysis. Eur J Clin Pharmacol 2018; 74 (03) 297-305
- 32 Chapin J. Von Willebrand disease in the elderly: clinical perspectives. Clin Interv Aging 2018; 13: 1531-1541
- 33 Rydz N, Grabell J, Lillicrap D, James PD. Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease. Haemophilia 2015; 21 (05) 636-641
- 34 Federici AB, Bucciarelli P, Castaman G. , et al. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients. Semin Thromb Hemost 2011; 37 (05) 511-521
- 35 Ng C, Motto DG, Di Paola J. Diagnostic approach to von Willebrand disease. Blood 2015; 125 (13) 2029-2037
- 36 Lavin M, O'Donnell JS. How I treat low von Willebrand factor levels. Blood 2019; 133 (08) 795-804
- 37 Juul KV, Klein BM, Sandström R, Erichsen L, Nørgaard JP. Gender difference in antidiuretic response to desmopressin. Am J Physiol Renal Physiol 2011; 300 (05) F1116-F1122
- 38 Liu J, Sharma N, Zheng W. , et al. Sex differences in vasopressin V2 receptor expression and vasopressin-induced antidiuresis. Am J Physiol Renal Physiol 2011; 300 (02) F433-F440
- 39 Liu J, Ji H, Zheng W, Verbalis J, Sandberg K. Gonadal hormone regulation of the renal vasopressin V2 receptor. FASEB J 2008; 22 (01) 1159
- 40 Sanders YV, van der Bom JG, Isaacs A. , et al; WiN Study Group. CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease. J Thromb Haemost 2015; 13 (06) 956-966
- 41 Smith NL, Chen MH, Dehghan A. , et al; Wellcome Trust Case Control Consortium. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation 2010; 121 (12) 1382-1392
- 42 Rydz N, Swystun LL, Notley C. , et al. The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels. Blood 2013; 121 (26) 5228-5237